Genmab A/S (GMAB.CO)
DKK 1486.5
(4.13%)
DKK 1486.5
(4.13%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 5.32 Billion DKK | -16.3% |
| 2022 | 6.35 Billion DKK | 110.64% |
| 2021 | 3.01 Billion DKK | -52.19% |
| 2020 | 6.31 Billion DKK | 139.31% |
| 2019 | 2.63 Billion DKK | 91.12% |
| 2018 | 1.38 Billion DKK | 2.69% |
| 2017 | 1.34 Billion DKK | 27.67% |
| 2016 | 1.05 Billion DKK | 44.15% |
| 2015 | 730.37 Million DKK | 175.43% |
| 2014 | 265.17 Million DKK | 170.96% |
| 2013 | 97.86 Million DKK | 183.88% |
| 2012 | -116.67 Million DKK | 53.22% |
| 2011 | -249.42 Million DKK | -55.22% |
| 2010 | -160.68 Million DKK | 67.74% |
| 2009 | -498.03 Million DKK | 23.24% |
| 2008 | -648.81 Million DKK | -48.43% |
| 2007 | -437.13 Million DKK | 7.43% |
| 2006 | -472.21 Million DKK | -10.35% |
| 2005 | -427.92 Million DKK | -196.97% |
| 2004 | 441.27 Million DKK | 228.95% |
| 2003 | -342.2 Million DKK | -154.99% |
| 2002 | 622.28 Million DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.81 Billion DKK | 104.74% |
| 2024 Q1 | 801 Million DKK | -52.04% |
| 2023 Q4 | 1.67 Billion DKK | -2.74% |
| 2023 Q2 | 1.49 Billion DKK | 242.56% |
| 2023 Q1 | 437 Million DKK | -90.9% |
| 2023 FY | 5.32 Billion DKK | -16.3% |
| 2023 Q3 | 1.71 Billion DKK | 14.7% |
| 2022 Q3 | 681 Million DKK | -45.39% |
| 2022 Q4 | 4.8 Billion DKK | 605.29% |
| 2022 Q1 | 514 Million DKK | -36.46% |
| 2022 Q2 | 1.24 Billion DKK | 142.61% |
| 2022 FY | 6.35 Billion DKK | 110.64% |
| 2021 Q2 | 787 Million DKK | 47.93% |
| 2021 Q1 | 532 Million DKK | -40.02% |
| 2021 Q4 | 809 Million DKK | -9.1% |
| 2021 Q3 | 890 Million DKK | 13.09% |
| 2021 FY | 3.01 Billion DKK | -52.19% |
| 2020 Q1 | 71 Million DKK | -96.74% |
| 2020 Q3 | 858 Million DKK | -80.92% |
| 2020 Q4 | 887 Million DKK | 3.38% |
| 2020 FY | 6.31 Billion DKK | 139.31% |
| 2020 Q2 | 4.49 Billion DKK | 6233.8% |
| 2019 FY | 2.63 Billion DKK | 91.12% |
| 2019 Q4 | 2.17 Billion DKK | 520.42% |
| 2019 Q3 | 350.73 Million DKK | 155.7% |
| 2019 Q2 | 137.16 Million DKK | 629.11% |
| 2019 Q1 | -25.92 Million DKK | -103.6% |
| 2018 Q2 | 135.04 Million DKK | -58.33% |
| 2018 FY | 1.38 Billion DKK | 2.69% |
| 2018 Q4 | 721.02 Million DKK | 260.2% |
| 2018 Q3 | 200.17 Million DKK | 48.23% |
| 2018 Q1 | 324.04 Million DKK | -53.93% |
| 2017 FY | 1.34 Billion DKK | 27.67% |
| 2017 Q2 | 536.41 Million DKK | 1064.35% |
| 2017 Q4 | 703.38 Million DKK | 1106.49% |
| 2017 Q3 | 58.3 Million DKK | -89.13% |
| 2017 Q1 | 46.07 Million DKK | -93.49% |
| 2016 Q2 | 141.78 Million DKK | 767.75% |
| 2016 FY | 1.05 Billion DKK | 44.15% |
| 2016 Q1 | 16.33 Million DKK | -95.65% |
| 2016 Q3 | 186.83 Million DKK | 31.78% |
| 2016 Q4 | 707.87 Million DKK | 278.88% |
| 2015 Q4 | 375.34 Million DKK | 163.07% |
| 2015 Q2 | 39.41 Million DKK | -77.21% |
| 2015 Q3 | 142.67 Million DKK | 261.97% |
| 2015 FY | 730.37 Million DKK | 175.43% |
| 2015 Q1 | 172.94 Million DKK | 182.52% |
| 2014 Q1 | 96.35 Million DKK | 80.71% |
| 2014 FY | 265.17 Million DKK | 170.96% |
| 2014 Q4 | 61.21 Million DKK | -56.06% |
| 2014 Q3 | 139.32 Million DKK | 539.37% |
| 2014 Q2 | -31.71 Million DKK | -132.91% |
| 2013 Q2 | -17.86 Million DKK | -161.39% |
| 2013 Q1 | 29.1 Million DKK | 468.62% |
| 2013 Q4 | 53.31 Million DKK | 1034.62% |
| 2013 FY | 97.86 Million DKK | 183.88% |
| 2013 Q3 | 4.69 Million DKK | 126.3% |
| 2012 Q1 | -44.14 Million DKK | 31.39% |
| 2012 Q2 | -37.38 Million DKK | 15.33% |
| 2012 Q3 | -27.25 Million DKK | 27.08% |
| 2012 Q4 | -7.89 Million DKK | 71.03% |
| 2012 FY | -116.67 Million DKK | 53.22% |
| 2011 Q1 | -61.73 Million DKK | 29.3% |
| 2011 Q2 | -65.43 Million DKK | -6.0% |
| 2011 Q4 | -64.34 Million DKK | -11.11% |
| 2011 FY | -249.42 Million DKK | -55.22% |
| 2011 Q3 | -57.91 Million DKK | 11.5% |
| 2010 Q1 | -146.5 Million DKK | -7.09% |
| 2010 FY | -160.68 Million DKK | 67.74% |
| 2010 Q3 | 166.93 Million DKK | 277.96% |
| 2010 Q4 | -87.31 Million DKK | -152.31% |
| 2010 Q2 | -93.8 Million DKK | 35.97% |
| 2009 Q2 | -176.32 Million DKK | -380.98% |
| 2009 FY | -498.03 Million DKK | 23.24% |
| 2009 Q1 | -36.65 Million DKK | 0.0% |
| 2009 Q4 | -136.8 Million DKK | 7.71% |
| 2009 Q3 | -148.24 Million DKK | 15.92% |
| 2008 FY | -648.81 Million DKK | -48.43% |
| 2007 FY | -437.13 Million DKK | 7.43% |
| 2006 FY | -472.21 Million DKK | -10.35% |
| 2005 FY | -427.92 Million DKK | -196.97% |
| 2004 FY | 441.27 Million DKK | 228.95% |
| 2003 FY | -342.2 Million DKK | -154.99% |
| 2002 FY | 622.28 Million DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ALK-Abelló A/S | 666 Million DKK | -698.949% |
| Bavarian Nordic A/S | 1.49 Billion DKK | -255.32% |
| Gubra A/S | -49.41 Million DKK | 10867.55% |
| Novo Nordisk A/S | 102.57 Billion DKK | 94.813% |
| Orphazyme A/S | -27.04 Thousand DKK | 19677626.719% |
| Pharma Equity Group A/S | -25.29 Million DKK | 21137.441% |
| Zealand Pharma A/S | -572.23 Million DKK | 1029.858% |